| Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer J Baselga, J Cortes, SB Kim New England Journal of Medicine 366, 109-119, 2012 | 3189 | 2012 |
| Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer SM Swain, J Baselga, SB Kim N Engl J Med 372, 724-734, 2015 | 2415 | 2015 |
| Integrated genomic and molecular characterization of cervical cancer CZG Burk Robert D NATURE 534 (7645), 378, 2017 | 1128* | 2017 |
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 … SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ... The Lancet Oncology 21 (4), 519-530, 2020 | 727 | 2020 |
| Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer EL Goode, MS Block, KR Kalli, RA Vierkant, W Chen, ZC Fogarty, ... JAMA oncology 3 (12), e173290-e173290, 2017 | 313 | 2017 |
| IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment L Benevides, DM da Fonseca, PB Donate, DG Tiezzi, DD De Carvalho, ... Cancer research 75 (18), 3788-3799, 2015 | 205 | 2015 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 115 | 2019 |
| Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL‐17A expression and invasiveness of the tumor L Benevides, CRB Cardoso, DG Tiezzi, HRC Marana, JM Andrade, ... European journal of immunology 43 (6), 1518-1528, 2013 | 113 | 2013 |
| Chemotherapy in the treatment of locally advanced cervical cancer and pregnancy HRC Marana, JM de Andrade, ÂC da Silva Mathes, G Duarte, ... Gynecologic oncology 80 (2), 272-274, 2001 | 110 | 2001 |
| Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement AH Macchetti, HRC Marana, JS Silva, JM Andrade, A Ribeiro-Silva, ... Clinics 61, 203-208, 2006 | 107 | 2006 |
| HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel … DG Tiezzi, JM Andrade, A Ribeiro-Silva, FE Zola, HRC Marana, MG Tiezzi BMC cancer 7, 1-10, 2007 | 106 | 2007 |
| Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO … A Braga, EM Uberti, M Viggiano, SY Sun, BM Grillo, SL Padilha, ... The Journal of reproductive medicine 59 (5-6), 241-247, 2014 | 86 | 2014 |
| Differential diagnosis of axillary masses JM de Andrade, HRC Marana, JMS Filho, EFC Murta, MASL Velludo, ... Tumori Journal 82 (6), 596-599, 1996 | 85 | 1996 |
| Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study PF Rambau, RA Vierkant, MP Intermaggio, LE Kelemen, MT Goodman, ... The Journal of Pathology: Clinical Research 4 (4), 250-261, 2018 | 81 | 2018 |
| Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens RA Abrão, JM de Andrade, DG Tiezzi, HRC Marana, FJC dos Reis, ... Gynecologic oncology 108 (1), 149-153, 2008 | 81 | 2008 |
| Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy EFC Murta, JM de Andrade, RP Falcio, S Bighetti Tumori Journal 86 (5), 403-407, 2000 | 77 | 2000 |
| Basal levels of DNA damage detected by micronuclei and comet assays in untreated breast cancer patients and healthy women RA Santos, AC Teixeira, MB Mayorano, HHA Carrara, JM Andrade, ... Clinical and Experimental Medicine 10, 87-92, 2010 | 75 | 2010 |
| Quality of life in women with breast cancer treated with or without chemotherapy MFB da Mata Tiezzi, JM de Andrade, APMS Romão, DG Tiezzi, MR Lerri, ... Cancer nursing 40 (2), 108-116, 2017 | 63 | 2017 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 60 | 2021 |
| Evolving concepts in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods TMG Oliveira, J Elias, AF Melo, SR Teixeira, SC Filho, LM Gonçalves, ... Insights into imaging 5, 183-194, 2014 | 56 | 2014 |
